Graviton BioScience Unveils Promising Preclinical Data for Treating Multiple Sclerosis with ROCK2 Inhibition

Graviton BioScience Presents New Insights at Neuroscience 2026



On November 15, 2026, Graviton BioScience Corporation took the stage at the Neuroscience 2026 conference to share groundbreaking preclinical data regarding their new selective ROCK2 inhibitor, GV300. This innovative therapy has shown significant promise in addressing multiple sclerosis (MS), a condition that has long challenged the medical community due to its debilitating effects on the central nervous system (CNS).

The findings presented by Julien Moretti, Ph.D., highlighted GV300's ability to effectively penetrate the blood-brain barrier, enhancing its therapeutic potential. With improved solubility and heightened oral bioavailability, GV300 has emerged as a compelling candidate for treating progressive forms of MS, which currently lack effective treatment options.

Key Findings from Preclinical Studies


Graviton’s research spanned several preclinical models, revealing several pivotal advantages of GV300:

1. Reduction of Neuroinflammation and Demyelination: In the Experimental Autoimmune Encephalomyelitis (EAE) model, which mimics MS, GV300 was administered orally and resulted in decreased clinical disease scores. The treatment also significantly lowered inflammation levels in the spinal cord while reducing biomarkers associated with neurodegeneration, illustrating its dual action of lowering both inflammation and damage in the CNS.

2. Promotion of Remyelination: In additional studies on a cuprizone-induced demyelination model, GV300 was shown to encourage remyelination. These results suggest that its benefits extend beyond merely modulating autoimmune responses, positioning GV300 as a dual-action therapy that also fosters repair mechanisms in the CNS.

3. Enhanced Mechanistic Pathways: Further investigation into the mechanisms of GV300 revealed that the inhibitor not only reduces inflammation but also enhances myelination. It supports oligodendrocytes in promoting myelin repair, increases the clearance of myelin debris by microglia, and stimulates neurite outgrowth.

These findings collectively underscore the potential of GV300 to simultaneously tackle various aspects of MS pathology, making it an especially promising candidate for treating progressive MS, where disease progression often occurs irrespective of inflammatory activity.

The Need for Effective Treatments


According to Samuel D. Waksal, Ph.D., the CEO of Graviton BioScience, the results of this research are particularly significant given the limited treatment options available for patients with progressive multiple sclerosis. Many current therapies primarily target peripheral inflammation, failing to address the more complex mechanisms of neurodegeneration and impaired repair within the CNS.

Dr. Waksal emphasized that GV300’s unique approach offers hope not just in controlling inflammation but also in restoring cell health and promoting myelin repair. The potential of selective ROCK2 inhibition could represent a paradigm shift in the treatment landscape for progressive MS, directly addressing its underlying causes rather than merely managing symptoms.

Looking Forward


Graviton BioScience’s commitment to furthering the development of GV300 and similar therapies reflects the company's dedication to tackling unmet medical needs. As the landscape of MS treatment evolves, the data from these preclinical studies certainly pave the way for future clinical trials that could confirm the efficacy and safety of GV300 in human populations.

As research continues, Graviton remains poised at the forefront of bioscience innovation, with the potential to redefine MS treatment and offer hope to countless patients grappling with this challenging condition.

The presentation entitled “Selective ROCK2 inhibitors ameliorate murine models of multiple sclerosis and demyelination by harnessing inflammation and restoring homeostasis,” marks a significant step forward in the exploration of targeted therapies that promise to improve quality of life for those affected by MS.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.